# EDGAR Filing Document

**Accession Number:** 0001590750
**File Stem:** 0001193125-26-160349
**Filing Date:** 2026-4
**Character Count:** 5344
**Document Hash:** 6d3480f5cf8df94cf67a5d109cad9466
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-160349.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001193125-26-160349

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Viridian Therapeutics, Inc.\DE
- **CENTRAL INDEX KEY:** 0001590750
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471187261
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36483
- **FILM NUMBER:** 26869453

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** SUITE 103A
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 617.272.4600

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT STREET
- **STREET 2:** SUITE 103A
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MIRAGEN THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20170213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SIGNAL GENETICS, INC.
- **DATE OF NAME CHANGE:** 20140710

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A INFORMATION** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**VIRIDIAN THERAPEUTICS, INC.** 

**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 103A <br> WALTHAM, MA 02453

V90121-P47649

![LOGO](g904274dsp2.jpg)

You invested in VIRIDIAN THERAPEUTICS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. **This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 2, 2026.**

Get informed before you vote

View the Proxy Statement, Notice, and Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 19, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

![LOGO](g904274dsp2a.jpg)

\*Please check the meeting materials for any special requirements for meeting attendance.

------

**Vote at www.ProxyVote.com** 

**THIS IS NOT A VOTABLE BALLOT** 

This is only an overview of the more complete proxy materials, which contain important information and are available on the internet or by mail. You may view the proxy materials at www.ProxyVote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to vote on these important matters.

---

| | | | |
|:---|:---|:---|:---|
| **Voting Items** | **Voting Items** | **Board**<br> **Recommends** | **Board**<br> **Recommends** |
| 1. | To elect the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders, and until their successors are duly elected and qualified. |  |  |
|  | **Nominees:** |  |  |
|  1a. | Tomas Kiselak | ![LOGO](g904274dsp3.jpg) | **For** |
|  1b. | Jennifer K. Moses | ![LOGO](g904274dsp3.jpg) | **For** |
| 2. | To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | ![LOGO](g904274dsp3.jpg) | **For** |
| 3. | To approve, on an advisory basis, the compensation of the Company's named executive officers. | ![LOGO](g904274dsp3.jpg) | **For** |
| 4. | To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company's named executive officers. | ![LOGO](g904274dsp3a.jpg) | **Year** |
| &nbsp;&nbsp; **NOTE:** To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. | &nbsp;&nbsp; **NOTE:** To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. |  |  |

---

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V90122-P47649